Billionaire Druckenmiller and Jim Cramer Like These Stocks

9. Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Number of Hedge Fund Holders: 60

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is among the stocks that Billionaire Druckenmiller and Jim Cramer like.

On April 29, 2026, Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced entering into a definitive agreement to acquire Emalex Biosciences. The transaction involves $700 million in cash, plus up to $200 million in milestone payments and royalties. Through the acquisition, the company gains access to ecopipam, a first-in-class selective dopamine D1 receptor antagonist for pediatric Tourette syndrome. Following positive Phase 3 results, ecopipam awaits an NDA in the second half of 2026. The transaction is anticipated to close by Q3 2026, with Teva Pharmaceutical Industries Limited (NYSE:TEVA) maintaining its 2027 financial targets despite the near-term investment.

Separately, Teva Pharmaceutical Industries Limited (NYSE:TEVA) reported its Q1 2026 earnings results on April 29, 2026, highlighting a 2% increase in revenue year-over-year to approximately $4 billion in USD. The company attributes the increase to its innovative portfolio growth and disciplined execution, despite facing headwinds in lenalidomide capsules. The company’s non-GAAP EPS of $0.53 surpassed the consensus estimate of $0.48 – $0.50.

Druckenmiller built a multi-quarter position on the stock before trimming in Q4 2025, while Cramer reversed his long-held skepticism and hosted the CEO in January 2026, praising a genuine turnaround.

The company brought in a new leader, Richard Francis, at the beginning of 2023, and the stock hasn’t looked back since, nearly 400% gain from its 2022 lows.

Founded in 1901, Teva Pharmaceutical Industries Limited (NYSE:TEVA) is a leading innovative biopharmaceutical company. The Israel-based company focuses on developing, manufacturing, marketing, and distributing generic and other medicines and biopharmaceutical products.